Which statement is true about the list of insulin types as described in the material?

Which statement is true about the list of insulin types as described in the material?

• A. Lispro, Regular, Ultralente, and NPH are listed
• B. Glargine is listed as an insulin type in the material
• C. Regular insulin is the only short-acting option listed
• D. NPH insulin is not listed

Answer: (A)

Insulin preparations are classified by how long they act after injection, covering rapid, short, intermediate, and long-acting profiles. The material’s list includes lispro (rapid-acting), regular (short-acting), NPH (intermediate-acting), and ultralente (long-acting), demonstrating a full range of action durations. That makes the statement true because it directly reflects the four insulin types described. Notes on the other ideas: glargine is another long-acting insulin, but it’s not mentioned in this material’s list, so claiming it is listed wouldn’t fit. Regular insulin is the standard short-acting option, but lispro is rapid-acting as well, so saying regular is the only short-acting option doesn’t match the described list. NPH is indeed listed, so stating that it’s not listed is inaccurate.

Insulin preparations are classified by how long they act after injection, covering rapid, short, intermediate, and long-acting profiles. The material’s list includes lispro (rapid-acting), regular (short-acting), NPH (intermediate-acting), and ultralente (long-acting), demonstrating a full range of action durations. That makes the statement true because it directly reflects the four insulin types described.

Notes on the other ideas: glargine is another long-acting insulin, but it’s not mentioned in this material’s list, so claiming it is listed wouldn’t fit. Regular insulin is the standard short-acting option, but lispro is rapid-acting as well, so saying regular is the only short-acting option doesn’t match the described list. NPH is indeed listed, so stating that it’s not listed is inaccurate.